TX-POWER-COSTS-INC
17.3.2021 11:02:10 CET | Business Wire | Press release
Brookfield Renewable Ireland Limited (“BRIL” or “Brookfield Renewable”) has gone live with PCI’s Enterprise Platform to manage its customer billing requirements in the Irish energy market.
As part of its partnership with Brookfield Renewable, PCI deployed its specifically tailored, cloud-based, integrated platform to replace the Irish business’ legacy system and several in-house applications. The new Customer Billing Solution implemented by PCI enables Brookfield Renewable to:
- Manage complex bilateral contracts, including power purchase agreements (PPAs)
- Leverage PCI’s settlements calculation business rules engine to perform billing allocation
- Perform counterparty checkouts and meter data management (MDM)
- Interface with upstream and downstream (physical, telemetered, and accounting) systems
- Maintain comprehensive auditability with all data versions
- Automate invoice creation and management workflows
- Drill-down and quickly extract data to perform reporting
BRIL Chief Commercial Officer Ciaran O'Brien noted, “We are excited at the launch of our new cloud-based customer billing system which will be transformational for our renewable energy business, bringing increased flexibility and supporting further growth with a scalable, best-in-class solution.” Adding, “We are proud to partner with PCI on this project and appreciate the professional collaboration with our team for an on-time and on-budget delivery.”
“We have found a great partner in Brookfield Renewable, one that has a matching ethos and customer-centric mindset. The successful go-live represents a major milestone for PCI’s global, remote software deployments that feature 24x7 operations,” said PCI Vice President Shailesh Mishra.
As part of the next phase of this project, Brookfield Renewable’s Irish business plans to leverage the PCI Platform to provide its customers with a dedicated application for on-demand access to energy data and enhanced reporting. PCI’s Platform offers unmatched functionality for renewable energy players to optimize their portfolios, including co-optimization of Energy Storage Systems (ESS) in wholesale power markets. PCI works with numerous renewable energy providers, including BHE Renewables, RWE Renewables, Iberdrola, Acciona, Xcel Energy, DTE Energy, and others.
About Brookfield Renewable
Brookfield Renewable operates one of the world’s largest publicly traded, pure-play renewable power platforms. Its portfolio consists of hydroelectric, wind, solar, distributed generation, and storage facilities in North America, South America, Europe, and Asia, and totals approximately 20,000 megawatts of installed capacity and an approximately 23,000-megawatt development pipeline.
Brookfield Renewable’s Irish onshore wind portfolio is a fully integrated development, operations, and renewable energy solutions business with 365 MW of operating capacity and a significant onshore wind development pipeline. Further information is available at www.brookfield.com/our-businesses/renewable-power .
About Power Costs, Inc. (PCI)
PCI is the leading provider of energy trading software, superior customer support, and value-added services for energy companies worldwide. Founded in 1992, PCI continues to refine and develop new solutions that meet the ever-evolving needs of its clients which include investor-owned, municipal, and cooperative utilities, renewable energy companies, energy marketers and traders, as well as independent power producers. PCI optimizes more than half the power generated in North America and more than 60% of Fortune 500 Utilities in the U.S. are PCI customers. The firm is privately held and based in Norman (OK) with regional offices in Houston (TX), Raleigh (NC), and Mexico City. To learn more, please visit www.powercosts.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005052/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom